Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475032 | 1.00 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AUSP30MAPT | |
| SCHEMBL969184 | 1.00 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AUSP30MAPT | |
| SCHEMBL2146383 | 0.93 | HSD11B1 (0.54) | ALDH1A1MEN1KMT2AUSP30 | |
| SCHEMBL1867513 | 0.89 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2AUSP30MAPT | |
| SCHEMBL4487414 | 0.88 | MEN1 (0.47) | ALDH1A1MEN1KMT2AUSP30LMNA | |
| SCHEMBL2328924 | 0.88 | USP30 (0.53) | ALDH1A1MEN1KMT2AUSP30MAPT | |
| SCHEMBL2328921 | 0.88 | USP30 (0.53) | ALDH1A1MEN1KMT2AUSP30MAPT | |
| SCHEMBL17913759 | 0.87 | LMNA (0.62) | ALDH1A1MEN1KMT2AUSP30MAPT | |
| SCHEMBL971485 | 0.87 | KDM2B (0.60) | ALDH1A1MEN1KMT2AUSP30MAPT | |
| SCHEMBL971486 | 0.87 | KDM2B (0.60) | ALDH1A1MEN1KMT2AUSP30MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2074108-B3 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2581366-A1 | Renin Inhibitors | Vitae Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2074108-B1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8198453-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008036216-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117560-A2 | PIPERIDINE AND MORPHOLINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | ALDH1A1 68/4885MEN1 1206/4885KMT2A 2279/4885 |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | ACE, PEPD, DNPEP | ALDH1A1 711/4885MEN1 3669/4885KMT2A 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.